EWTX
Edgewise Therapeutics, Inc.
Key Financials
Operating Income
$-191406000
↓ 20.5%
Net Income
$-167795000
↓ 25.4%
Total Assets
$552.6M
↑ 13.5%
Cash & Equivalents
$61.1M
↑ 46.8%
Shareholders' Equity
$522.3M
↑ 13.7%
Total Liabilities
$30.3M
↑ 9.9%
EPS (Diluted)
$-1.63
↓ 12.4%
Long-term Debt
$59000.00
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/1/2026 | View on SEC |
| 144 | 7/1/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 8-K | 6/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EWTX |
| Company Name | Edgewise Therapeutics, Inc. |
| CIK | 1710072 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 720-262-7002 |